



## ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also help reduce the social and economic burden of disease.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

## INNOVATIVE MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

## TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

## WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.



## AMGEN QUICK FACTS

### HEADQUARTERS

Thousand Oaks, California

### STAFF

Approximately 22,000  
worldwide

### STOCK LISTING

NASDAQ: AMGN

### CHAIRMAN AND CEO

Robert A. Bradway

### 2019 FINANCIAL HIGHLIGHTS

- Total revenue: USD 23.4 billion
- Product sales: USD 22.2 billion
- R&D expense: USD 4.0 billion

### MISSION

To serve patients

### VALUES

- Be Science-Based
- Compete Intensely and Win
- Create Value for Patients, Staff and Stockholders
- Be Ethical
- Trust and Respect Each Other
- Ensure Quality
- Work in Teams
- Collaborate, Communicate and Be Accountable

## ABOUT AMGEN AUSTRALIA

Established in 1991, Amgen Australia works to further the company's global efforts to transform the promise of science and biotechnology into therapies that restore health and save lives. Hundreds of thousands of Australians use one of Amgen's 15 products and thousands more have been enrolled in clinical studies that have helped deliver the next generation of innovative treatments. Amgen Australia is proud to support these patients and to contribute to the development of new therapies in partnership with Australia's leading healthcare, academic, research, government and patient organisations.

## LOCAL RESEARCH AND DEVELOPMENT

Amgen maintains an extensive clinical trial program and invests significantly in research and development. Amgen's history of clinical trial activity in Australia dates back over 30 years and our reputation for quality and safety continues to make us one of the most trusted destinations in the world for Amgen research. In 2019, this included 473 Australian patients, participating in 48 clinical trials and over 20 investigator sponsored studies, at more than 60 leading Australian hospitals.

## COMMUNITY SUPPORT

At the heart of Amgen Australia's operations is a genuine desire to make a positive impact, not only in the lab, but also in the wider community. This is realised through:

**The Amgen Foundation** – bringing the excitement of discovery to the scientists of tomorrow through signature programs including The Amgen Biotech Experience and Amgen Scholars.

The Amgen Biotech Experience, launched in Australia in 2017 through a partnership with The University of Sydney, provides professional development for teachers as well as teaching materials and research-grade equipment to classrooms to help educate high school students about the concepts and techniques scientists use to produce medicines.

Amgen Scholars, a partnership with The University of Melbourne which launched in 2018, provides hands-on research experience in leading laboratories to undergraduate science students across Australia, New Zealand and Oceania. For further information on Amgen's commitment to STEM education, visit our website.

**Local grants** – making a difference by enabling the work of others, particularly in the areas of clinical research and ongoing medical education.

**Patient organisations** – supporting Rare Cancers Australia, Osteoporosis Australia, Heart Foundation, Kidney Health Australia and others in their efforts to provide information, support and resources that improve prevention, diagnosis, treatment and survival.

**Volunteering** – providing staff with two days of paid charity leave so they can donate man-hours to important local community groups and projects. Through Amgen's Annual Day of Service in 2019, staff contributed over 700 hours of help and support to people and organisations in need.

**Environmental sustainability** – designing practices to measure and reduce environmental impact and build a culture of environmental awareness amongst employees.

## REWARDING CAREERS

Amgen Australia offers rewarding career opportunities for experienced professionals. Our dedicated and accomplished team bring curiosity, energy and optimism to prevail over ever-evolving challenges. Amgen is an Equal Employment Opportunity / Affirmative Action employer committed to building an environment of diversity, inclusion and belonging that fosters innovation, strengthens our global workforce and drives our ability to serve patients. Visit our website to learn more or to be considered for employment opportunities.

## AMGEN QUICK FACTS

### AUSTRALIAN OFFICE

Level 7, 123 Epping Road  
North Ryde NSW 2113  
T: +61 2 9870 1333  
F: +61 2 9870 1344  
W: [www.amgen.com.au](http://www.amgen.com.au)  
ABN 31 051 057 428

### MEDICAL INFORMATION

T: 1800 803 638 (toll free)

### MANAGING DIRECTOR

Shannon Sullivan

### 2019 REVENUE

AUD 359 million

### STAFF

230 permanent employees

### PRODUCTS

Aranesp® (darbepoetin alfa)  
BLINCYTO® (blinatumomab)  
KANJINTI® (trastuzumab)  
KYPROLIS® (carfilzomib)  
Neulasta® (pegfilgrastim)  
NEUPOGEN® (filgrastim)  
Nplate® (romiplostim)  
OTEZLA® (apremilast)  
Prolia® (denosumab)  
Repatha® (evolocumab)  
RISTEMPA® (pegfilgrastim)  
Sensipar® (cincalcet)  
TEZMOTA® (pegfilgrastim)  
Vectibix® (panitumumab)  
XGEVA® (denosumab)

For further information about our pipeline and therapies, visit [www.amgen.com.au](http://www.amgen.com.au)

### AFFILIATIONS

Amgen is a proud member of:

- Medicines Australia
- AusBiotech
- American Chamber of Commerce in Australia (AmCham)
- Australian Packaging Covenant Organisation